A report from Piper Jaffray reiterates its Neutral rating and lowers its price target from $89 to $87 on Allergan AGN.
The report states, “…cautious management commentary on the aesthetics business in North America reinforces our view that AGN shares are nearly fully valued. Our price target is now $87, down from $89, reflecting slight downward revisions to our EPS estimates."
AGN closed yesterday at $86.96.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in